Results 231 to 240 of about 39,697 (260)
Some of the next articles are maybe not open access.
Commentary on ‘Treatment-resistant major depressive disorder and assisted dying’
Journal of Medical Ethics, 2015Schuklenk and van de Vathorst (henceforth “the authors”) make the following starting assumption, which I will accept: that it is ethically permissible for doctors to assist suicide and it is permissible for those competent patients with terminal somatic diseases (such as inoperable stage IV cancer) or non-terminal but untreatable debilitating diseases (
openaire +2 more sources
Magnetic Seizure Therapy of Treatment-Resistant Depression in a Patient With Bipolar Disorder
The Journal of ECT, 2009Electroconvulsive therapy (ECT) is a highly efficacious treatment for severe depression. However, a disadvantage of ECT is the risk of cognitive side effects. Magnetic seizure therapy (MST) is a novel treatment modality, by which therapeutic seizures are induced using rapidly alternating strong magnetic fields.
Sarah, Kayser +3 more
openaire +2 more sources
Use of Electroconvulsive Therapy in Adolescents With Treatment-Resistant Depressive Disorders
The Journal of ECT, 2015This study presents a comprehensive case series of adolescents who received electroconvulsive therapy (ECT) for treatment-resistant depression.Conducting a chart review, we identified 13 adolescents who had ECT for treatment of depression over a 5-year interval (2008-2013) at a Canadian tertiary care psychiatric hospital.
Naista, Zhand +2 more
openaire +2 more sources
Expert Review of Neurotherapeutics, 2019
Introduction: Approximately 50% of adults with major depressive disorder (MDD) who receive a first-line antidepressant treatment, at an appropriate dose, do not achieve an adequate response. Brexpiprazole is a novel serotonin-dopamine activity modulator in the second generation/atypical antipsychotic class that was approved by the United States Food ...
Danielle S. Cha +5 more
openaire +5 more sources
Introduction: Approximately 50% of adults with major depressive disorder (MDD) who receive a first-line antidepressant treatment, at an appropriate dose, do not achieve an adequate response. Brexpiprazole is a novel serotonin-dopamine activity modulator in the second generation/atypical antipsychotic class that was approved by the United States Food ...
Danielle S. Cha +5 more
openaire +5 more sources
European Child & Adolescent Psychiatry, 2019
To update a comparative effectiveness review (1980-2011) of treatments for adolescents whose depressive episode or disorder (MDE/MDD) did not respond to one or more trials of SSRI antidepressants. MEDLINE, Cochrane Central, PsychINFO, Cochrane Database of Systematic Reviews, EMBASE, CINAHL, and AMED were searched in addition to the grey literature.
Khrista, Boylan +4 more
openaire +2 more sources
To update a comparative effectiveness review (1980-2011) of treatments for adolescents whose depressive episode or disorder (MDE/MDD) did not respond to one or more trials of SSRI antidepressants. MEDLINE, Cochrane Central, PsychINFO, Cochrane Database of Systematic Reviews, EMBASE, CINAHL, and AMED were searched in addition to the grey literature.
Khrista, Boylan +4 more
openaire +2 more sources
Ketamine: Clinical Studies in Treatment-Resistant Depressive Disorders
2016Since the first report of a robust antidepressant effect of a sub-anesthetic dose of ketamine in 2000, studies have repeatedly confirmed its therapeutic benefits in major depressive disorder (MDD) as well as in depressive episodes in patients with bipolar disorder (BD). Two features of the antidepressant response to ketamine make it striking: first, it
Pierre Blier, Jean Blier
openaire +1 more source
Topiramate in treatment‐resistant depression and binge‐eating disorder
Bipolar Disorders, 2002Pedro Antônio, Schmidt do Prado-Lima +1 more
openaire +2 more sources
Genomic Studies of Treatment Resistance in Major Depressive Disorder
2016Treatment-resistant depression describes the subset of individuals with major depressive disorder who do not reach symptomatic remission despite multiple adequate treatment trials. While treatment resistance has a substantial impact on functioning, quality of life, and healthcare costs, little is known about the underlying neurobiology.
openaire +1 more source
Treatment-Resistant Depression or Misdiagnosed Anxiety Disorder?
Journal of Nervous & Mental Disease, 2016Edward K, Silberman, Kenneth J, Weiss
openaire +2 more sources